

YKP3089

S. James Lee, PhD

SK Life Science, Fair Lawn, New Jersey

YKP3089 is a novel neurotherapeutic compound under development at SK Life Science. It has potential to be a versatile CNS drug with efficacy in epilepsy, neuropathic pain, anxiety and bipolar disorder, among others.

YKP3089 show efficacy in a broad spectrum of animal models of epilepsy. YKP3089 is efficacious in the animal models of neuropathic pain. In addition, positive effects were observed in many animal models of anxiety.

The novel compound shows a high safety margin with low potential for cardiovascular, genotoxicity and teratogenicity.

Phase 1 and 2 clinical trials were completed in the United States and data show a favorable PK profile with a half-life suggesting once-per-day dosing. YKP3089 was well-tolerated in single and multiple dose clinical trials with low incidence of adverse effects.

The Proof of Concept for epilepsy effect was demonstrated in epilepsy photosensitivity response study. The full development for epilepsy is underway, along with development for neuropathic pain and other indications.